Biccler JL, et al. - Based on a Nordic cohort of 2,582 patients who received the diagnosis of classic Hodgkin lymphoma (cHL) between 18 to 49 years of age from 2000 to 2013, researchers assessed cHL prognosis at different milestones during follow-up. For all patients and for those who achieved event-free survival (EFS) for 12 (EFS12), 24 (EFS24), 36 (EFS36) or 60 (EFS60) months, they assessed 5-year relapse risks and 5-year restricted losses in expectation of lifetime. The estimated 5-year overall survival was 95%. They noted a 13.4% overall 5-year risk of relapse which declined to 4.2% if patients reached EFS24. Treatment with six to eight courses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) resulted in a relapse risk that was similar to that seen with six to eight courses of doxorubicin, bleomycin, vinblastine, and dacarbazine, despite more adverse risk criteria in patients treated with BEACOPP. Overall outstanding outcomes were seen in young patients with cHL from the Nordic countries. Limited relapse-oriented clinical follow-up was supported by a particularly favorable outlook reported for patients who reached EFS24.